Headlines about Horizon Therapeutics (NASDAQ:HPTX) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Horizon Therapeutics earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.8301226256293 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of NASDAQ:HPTX remained flat at $$45.99 during mid-day trading on Monday. Horizon Therapeutics has a 12-month low of $20.23 and a 12-month high of $46.96.
About Horizon Therapeutics
Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.
No comments:
Post a Comment